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ABSTRACT 
Background and aims: Data about the efficacy of the intercellular adhesion molecule-1 (ICAM-
1) antisense oligonucleotide termed alicaforsen in ulcerative colitis (UC) is inconsistent. (1) We 
have recently suggested a role for alicaforsen in the treatment of refractory pouchitis. (2) This 
case series on 12 UC patients reports on the efficacy in left-sided UC and proctitis. Methods: 
We performed a retrospective analysis on all patients who had received at least one dose of 
Alicaforsen at six referral centers in Switzerland. We assessed the drug`s efficacy in patients 
treated for left-sided UC and proctitis by comparing clinical and/or – if applicable – endoscopic 
disease activity scores before and after treatment. Results: 12 patients were treated for left-
sided UC or proctitis. 11 patients received a full 6-week course of a once-daily 240mg 
alicaforsen enema formulation, in 1 patient treatment was early discontinued due to lack of 
efficacy. Off-label Alicaforsen was chosen in the majority of patients in order to defer systemic 
treatment despite a severe disease course (6/12, 50.0%). Clinical disease activity measured 
by the partial Mayo score and a 6-point symptom score (adapted from the Mayo Score) was 
significantly reduced after treatment (6.0 vs. 2.4, p=0.011 and 3.7 vs. 1.4, p=0.008, 
respectively). Fecal calprotectin was considerably reduced after alicaforsen treatment (484.4 
vs. 179.5μg/g), however the difference did not reach statistical significance (p=0.063). Clinical 
improvement was achieved in 10 out of the 12 patients (83.3%). However in 7 of those, a 
relapse occurred (70%). Median duration of clinical response was 18.0 weeks (range 1-112). 
Three patients showed an ongoing response of more than 9 months. No adverse events were 
reported. Conclusions: A 6-week course of Alicaforsen as enema formulation seemed to be 
safe and efficacious in inducing clinical improvement in patients with left-sided UC and 
proctitis. Prolonged response was observed in many, but not all patients.   
 
 
 
 
INTRODUCTION 
Gut-selective immunosuppressive agents such as Vedolizumab or Mongersen are very 
promising given their similar efficacy, but lower rates of side-effects compared to anti-TNF 
treatment. (3-5) Infectious complications of anti-TNF remain a significant concern in clinical 
treatment decision and development of highly gut-selective therapies interacting with gut 
inflammation but preserving systemic immune response have become a priority in the field of 
inflammatory bowel disease (IBD) research. (6) Such therapies take advantage of the specific 
molecular interactions in leukocyte trafficking. (7) Leukocyte trafficking is a multistep process 
involving both the -immune and the endothelial cell, which enables direction of leukocytes to 
the site of inflammation: leukocytes tether, get activated, adhere to the endothelium and finally 
migrate through the endothelial layer. For this sequence, interaction between proteins on the 
surface of leukocytes and their corresponding ligands are crucial: integrins are expressed on 
immune cells and bind to their counterpart molecules of the immunoglobulin superfamily on 
endothelial cells. The latter consist of intercellular adhesion molecule-1 (ICAM-1), vascular cell 
adhesion molecule (VCAM) or mucosal vascular addressin cell adhesion molecule (MAdCAM). 
While MAdCAM interacts with α4β7 integrin, which is therefore causative for the efficacy of 
vedolizumab, ICAM-1 is a transmembrane glycoprotein expressed on the surface of intestinal 
epithelial cells and vascular endothelial cells that binds to β2 integrins and therefore promotes 
firm adhesion of leukocytes to the endothelium. (8, 9) Expression of ICAM-1 is upregulated by 
TNFα, interleukin-1, interferon-γ (IFNγ) and/or lipopolysaccharide (LPS). (10) Inflammation 
triggered by those factors (such as in IBD) results in an increased leukocyte adhesion and 
trafficking. Several studies suggest that an increased expression of ICAM-1 is a part of the 
pathology of IBD, (11-16) which has led to the idea of blocking the ICAM-1 pathway in IBD 
treatment. 
 
Alicaforsen is a human ICAM-1 antisense oligonucleotide, which blocks ICAM-1 production by 
complementary hybridization to the messenger ribonucleic acid (mRNA) of the target gene 
resulting in hydrolysis of the created deoxyribonucleic acid-ribonucleic acid (DNA-RNA) 
complex by a RNase enzyme. (17) While the systemic administration of Alicaforsen in Crohn`s 
disease (CD) was not efficacious (18-20) and two randomized-controlled trials evaluating the 
role of topical alicaforsen in UC failed to show short-term efficacy, patients treated with the 
enema formulation seemed to have a long-term benefit. (1, 21, 22) This has led to the 
hypothesis of a disease-modifying effect. In addition, two small open label studies evaluating 
the role of Alicaforsen in chronic pouchitis have shown promising results even in difficult to 
treat cases. (2, 23) 
 
Taken together, there might be a role for topical Alicaforsen in the treatment of chronic 
pouchitis and left-sided UC. This case series analyzes the efficacy and safety of a 6-week 
course of Alicaforsen as enema formulation in the treatment of left-sided UC and ulcerative 
proctitis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
METHODS 
Subjects 
We performed a retrospective analysis on all patients who had received at least one dose of 
Alicaforsen at six IBD referral centers in Switzerland with at least one follow-up visit (University 
Hospital Zurich, Triemli Hospital Zurich, Gastrozentrum Hirslanden Zurich, Tiefenauspital 
Bern, Kantonsspital St. Gallen, and the outpatient clinic MagenDarm AG Basel). Patient 
information was extracted from each patient’s chart. Patients were excluded if they were under 
the age of 16. Diagnosis of underlying IBD had to be established based on clinical course, 
endoscopy and histology according to current international guidelines. As Alicaforsen has 
currently an off-label status in Switzerland, approval from the patient`s health care insurance 
for reimbursement and from the Swiss Agency for Therapeutic Products (SwissMedic) was 
needed prior to the first administration. For a detailed outcome analysis, only patients treated 
for left-sided UC and/or ulcerative proctitis were included. All patients were currently enrolled 
in the Swiss IBD Cohort Study, which an ethical approval is available for. Written informed 
consent had been obtained from every patient.  
 
Data collection 
The following data was collected from individual`s patient charts: patient demographics (sex, 
age, smoking status), prior medical and surgical history, prior therapies and current co-
medications, disease characteristics (age at disease onset, disease localization, disease 
course), laboratory parameters (full blood count, C-reactive protein (CRP), BSR, fecal 
calprotectin), endoscopic findings (if applicable), symptom severity (stool frequency, rectal 
bleeding). In order to grade clinical disease activity we used the partial Mayo Score and a 6-
point symptom score adapted from the Mayo Score, (24) which both had been used in UC 
studies. (25) In addition, disease activity was globally assessed by the treating physician based 
on his interpretation of clinical, endoscopic and histological findings ranging from remission to 
mild, moderate, and severe activity. If applicable, total Mayo score was calculated. We further 
collected all data on the use of Alicaforsen including exact indication, dosage, duration and 
side-effects.  In order to evaluate the efficacy of Alicaforsen, we used the following definitions 
of clinical improvement in accordance to our prior study evaluating alicaforsen in chronic 
pouchitis: (2) 
 
Presence of all of the following criteria: 
- Reduction of stool frequency 
- Reduction of partial Mayo Score and/or 6-point symptom score 
- Responsible clinician considers disease course as improvement in synopsis of clinical 
symptoms, quality of life and – if applicable – endoscopic findings. 
 
Last visit within 3 months before initiation of Alicaforsen was taken as pre-treatment evaluation. 
Endoscopic findings were excluded if endoscopy was performed >1 year before baseline 
assessment. Re-assessment of disease activity had to be done within 6 months after treatment 
initiation. Relapse was defined as increasing clinical and/or endoscopic disease activity after 
a period of clinical improvement. Duration from clinical improvement to first relapse was 
recorded for Kaplan Meier analysis. 
 
Statistical analysis 
For all statistical analyses, SPSS version 22.0.0 (2013 SPSS Science, Inc., Chicago, IL) was 
used. Metric data is shown as medians with total range. Categorical data are summarized as 
the percentage of the group total. For outcome analysis (before vs. after), Wilcoxon signed 
rank test was used for ordinary data and for continuous variables as they showed a non-normal 
distribution. For calculation of the clinical improvement-to-relapse-time, a Kaplan Meier 
analysis was performed. A two-sided p-value of <0.05 was regarded as statistically significant. 
 
 
RESULTS 
Overview of patients treated with alicaforsen 
We identified 30 patients with at least one-follow-up visit, who had received at least one dose 
of Alicaforsen. Median age was 37.5 years (17.0-69.5) when treatment with Alicaforsen was 
initiated. 29 patients suffered from UC, while 1 patient had been diagnosed with CD. Median 
age at IBD diagnosis was 24.4 years (7.5-59.0). At the time of initiation of Alicaforsen, median 
duration of IBD was 12.8 years (1.5-43.2). Indication for Alicaforsen treatment was as follows: 
12 patients were being treated for left-sided UC or proctitis, while 16 were treated for chronic 
pouchitis after proctocolectomy, 1 patient was treated for CD proctitis and 1 patient for 
ischemic pouchitis. In only 2 patients (1 treated for CD proctitis and 1 for left-sided UC colitis), 
Alicaforsen was discontinued early after 10 days and 5 weeks, respectively. In both cases, 
lack of efficacy was the reason for early discontinuation. 24 of the 30 patients showed an 
improvement of the underlying condition based on physician`s global assessment. 19 of those 
patients experienced a relapse with a median duration from improvement to relapse of 12 
weeks (1-112). No adverse events were reported. Results of those patients treated for chronic 
refractory pouchitis have been published in a prior case series. (2) Demographic data of all 
patients are depicted in Table 1. Supplementary Table 1 shows a synopsis of all 30 patients 
treated with at least one dose of alicaforsen. 
 
Patients treated for left-sided UC/proctitis 
The 12 patients treated for left-sided UC or proctitis had a median age of 36.7 years (range 
17.0-69.5). 5 patients were female (41.7%). Median age at UC diagnosis was 25.0 years (7.5-
59.0). Median duration of UC at initiation of Alicaforsen treatment was 11.8 years (1.5-14.8). 7 
of the 12 patients (58.3%) had left sided UC (Montreal Classification E2), while the remaining 
5 patients (41.7%) suffered from ulcerative proctitis (Montreal Classification E1). Table 2 
depicts demographic data and disease characteristics of those 12 patients treated for left-sided 
UC/proctitis. No history of C. difficile infection was reported, while 1 patient previously had had 
a CMV colitis. 4 patients were prior smokers. One patient with proctitis had previously 
undergone left-sided hemicolectomy due to sigma perforation. 11 of the 12 patients (91.7%) 
received a full 6-week course of 240mg Alicaforsen once-daily as enema formulation, while in 
1 patient Alicaforsen was early discontinued after 5 weeks due to lack of efficacy. No adverse 
events were reported.  Indication for the off-label use of Alicaforsen were: to defer systemic 
treatment despite a severe disease course (6/12, 50.0%), malcompliance with oral medications 
(1/12, 8.3%), severe course despite prior topical steroids and immunosuppressive agents 
(1/12, 8.3%), pregnancy with 5-ASA intolerance (1/12, 8.3%), and left sided UC before switch 
of anti-TNF (2/12, 16.7%). Physician`s global assessment revealed a moderate-to-severe 
disease activity in 10 out of 12 patients (83.3%). Only two patients were assessed to have mild 
disease. No patient was in remission. At baseline, median Mayo Score was 9.0 (4.0-11.0), 
partial Mayo Score was 7.0 (1.0-8.0) and 6-point symptom score was 4.5 (0.0-5.0). Patients 
reported a median of 7 stools per day (1-10). For a comprehensive synopsis on each individual 
patient, we refer to the supplementary tables 2 and 3. 
 
Overall study outcome 
Median follow-up (time from treatment initiation to first follow-up visit) was 3.0 months (1.6 - 
5.5 months). 6 of the 12 patients were treated with Alicaforsen alone, while the remaining 6 
patients received concomitant therapy: 1 patient was treated with overlapping prednisone, 
which was tapered within the first 2 weeks, 1 patient was treated with overlapping prednisone 
for 2 weeks and ongoing therapy with azathioprine and 5-ASA, 1 patient was concomitantly 
treated with ongoing topical budesonide and 5-ASA, 1 patient continued with oral and topical 
5-ASA, 1 patient continued with oral 5-ASA, azathioprine and certolizumab pegol, and 1 patient 
continued with infliximab. Clinical disease activity was significantly reduced at the first follow-
up visit. Mean partial Mayo score and the 6-point symptom score (adapted from Mayo Score) 
showed a decrease from 6.0 to 2.4 and from 3.7 to 1.4, respectively (p=0.011 and p=0.008). 
Total Mayo score and stool frequency both showed a relevant decrease from 8.6 to 5.3 and 
from 6.2 to 4.0, however differences were not statistically significant (p=0.092 and p=0.074). 
In 5 patients no follow-up endoscopy was performed. Fecal calprotectin as a marker of 
intestinal disease activity was considerably reduced after Alicaforsen treatment (mean 484.4 
vs. 179.5μg/g), however the difference did not reach statistical significance (p=0.063), as a 
complete set (both pre- and post-treatment) was available only for 7 of the 12 patients. Similar 
results were seen, if those patients having mild disease at treatment initiation were excluded 
– as those are less likely to benefit from Alicaforsen: Mayo Score 9.5 vs. 6.8 (p=0.197), partial 
Mayo Score 6.8 vs. 2.9 (p=0.020), 6-point symptom score 4.2 vs. 1.7 (p=0.013), stool 
frequency 7.15 vs. 4.6 stools/day (p=0.110) and fecal calprotectin  554.8ug/g vs. 208.0 (p= 
0.075). 
Clinical improvement was achieved in 10 out of the 12 patients (83.3%). Median duration of 
clinical response was 18.0 weeks (1.0-112.0). In 7 of the 10 patients with clinical improvement, 
a relapse was observed (70%). Median time from response to relapse was 6 weeks (1.0-
112.0). Three patients showed a sustained clinical response; in those patients, duration of 
clinical response was 36, 69 and 73 weeks, respectively. Figure 1 A-D shows clinical disease 
activity (Partial Mayo score (A), 6-point symptom scale (B), Mayo score (C) and fecal 
calprotectin (D)) at baseline versus at first follow-up visit after treatment. Figure 2 shows 
Kaplan-Meier analysis of duration of clinical response. 
 
 
 
 
 
 
 
DISCUSSION 
This retrospective case series analyzes the efficacy and safety of Alicaforsen as enema 
formulation in the treatment of left-sided UC and ulcerative proctitis in 12 patients in 
Switzerland. After a median of 3 months, patients treated with a 6-week course of Alicaforsen 
showed a significant reduction in clinical disease activity (as assessed by partial Mayo score 
and 6-point symptom score). We found that 10 out of 12 patients showed a clinical response 
to Alicaforsen; however, in 7 of those (70%) a relapse occurred. Median duration of clinical 
response was 18.0 weeks. In three patients with a sustained response, duration of clinical 
improvement was more than 9 months.  
 
Data on the potential role of Alicaforsen in IBD treatment is inconsistent. In CD, randomized-
controlled trials with intravenous/subcutaneous drug formulation failed to show short-term 
efficacy of Alicaforsen (at week 12 and 14, respectively), although post-hoc analysis suggested 
higher response rates with higher drug concentrations. (18-20, 26) In left-sided UC, In a small 
open label study Miner at al. could demonstrated that Alicaforsen enema provides local 
treatment without meaningful systemic exposure; at week 6, disease activity index was 
reduced by 46% with 12 out of 15 patients having achieved clinical improvement. (27) Two 
larger randomized-controlled trials by van Deventer and Minder failed to show (short-term) 
efficacy of the enema formulation: disease activity at week 6 was not significantly reduced 
compared to placebo and mesalazine, respectively. (1, 21) Nonetheless, a prolonged clinical 
response was observed in both trials with a significant reduction in disease activity at week 18 
and 30 compared to placebo (51 vs. 18% and 50 vs. 11%) and a significant longer duration of 
response compared to mesalazine (146 vs. 54 days). In a smaller randomized-controlled trial 
van Deventer et al. showed both a short-term and long-term benefit from Alicaforsen enema 
treatment: disease activity was reduced by 78% at day 29 and by 68% at 3 month compared 
to a placebo response of 28% and 11.5%, respectively. (28) Given the fact, that the half-life 
period of Alicaforsen is only 24 hours, these findings have led to the concept of a disease-
modifying effect. 
Our results with a clear and fast reduction of clinical disease activity (Mayo score –27%, partial 
Mayo score –60%, and 6-point symptom score –62%) are consistent with the open label study 
by Miner et al. and the small randomized-controlled trial by van Deventer. (27, 28) The clinical 
improvement rate of 83.3% (10 out of 12) is comparable to that of Miner at al. (clinical 
improvement in 12/15 patients (80%)). (27) These findings highlight the potential short-term 
benefit from a single 6-week course of Alicaforsen. However, 7 of the 10 patients with initial 
clinical improvement had a clinical relapse. The median duration of response of 18.0 weeks 
(corresponding to 126 days) is nearly as high as indicated by Miner et al (146 days). (21) Four 
patients had a response of more than 9 months, 3 of them without any further IBD treatment, 
the remaining patient with ongoing topical and oral 5-ASA only. 4 patients had a clinical 
improvement of less than or equal to 8 weeks. It remains to be determined, which patients 
show a prolonged response after a single 6-week course of Alicaforsen and which patients do 
not. Repeated treatment courses and/or maintenance therapy may lead to longer response 
rates as it has been reported in the case series regarding Alicaforsen in the treatment of 
chronic pouchitis. (2) So far, none of our patients had received a second trial due to the off-
label use of Alicaforsen and the difficulty of reimbursement by the Swiss health care 
insurances. 
 
No serious adverse events were reported underlying the safety of the topical applied drug. In 
addition, topical delivery was well tolerated and none of the patients showed malcompliance. 
to  
 
A limitation of our case series certainly is its retrospective nature and subsequently the lack of 
controls and blinding. 6 patients (50%) received concomitant treatment. However, 4 of the 6 
patients only continued the medications, which they had been on for a long time. In 2 patients, 
oral prednisone was tapered. The tapering of the steroids was well tolerated under Alicaforsen 
treatment.  The two patients with prior and ongoing anti-TNF exposure did show the worst 
outcome (1 patient with no response, 1 patient with a relapse after 1 week). The concern that 
anti-TNF co-medication may have affected the study outcome positively, seems to be 
negligible. In contrast, failure to respond to anti-TNF may be a negative predictor for treatment 
success with Alicaforsen.  
The presented results are based on the partial Mayo score and the 6-point symptom score 
(adapted from the Mayo score). Full Mayo score was only applied in 7 of the 12 patients due 
to the lack of follow-up endoscopies. However, both the partial score and the symptom score 
have been previously validated for UC. (25) The study population was limited due to the off-
label drug use and difficulty in reimbursement of the study drug from health care insurances. 
However, the study sample was nearly equal to that of the open label study by Miner et al. (27) 
 
In conclusion, a 6-week course of Alicaforsen was safe and showed seom efficacy in inducing 
clinical improvement in left-sided UC and proctitis, and is – at least in some patients – sufficient 
for maintaining clinical response. Further studies with more patients are needed to answer the 
question, which patients may benefit from a single 6-week course and which patients may 
need repeated treatment courses. 
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Nr Sex Age in 
years  
IBD Age at diagnosis Indication for 
treatment 
Duration of 
treatment (in 
weeks) 
Early discontinuation Response Duration Relapse Ongoing 
response 
ADE 
1 f 44.2 UC 38.6 Left-sided Colitis 6 No Yes 112 Yes No No 
2 m 36.3 UC 23.7 Left-sided Colitis 6 No Yes 18 Yes No No 
3 m 21.2 UC 7.5 Proctitis 6 No Yes 73+ No Yes (73 weeks 
+) 
No 
4 m 17.0 UC 15.5 Proctitis 6 No Yes 69+ No Yes (69 weeks 
+) 
No 
5 f 37.0 UC 22.5 Left-sided Colitis 6 No Yes 8 Yes No No 
6 f 46.0 UC 33.2 Left-sided Colitis 6 No Yes 1 Yes No No 
7 F 30.6 UC 25.0 Proctitis 6 No No    No 
8 F 28.5 UC 25.7 Proctocolitis 6 No Yes 1 Yes No No 
9 NA NA UC NA Proctitis 6 No Yes NA Yes No No 
101 m 57.6 UC 42.9 Pouchitis 6 No Yes 3 Yes No No 
111 f 59.8 UC 38.0 Pouchitis 6 No Yes 12 Yes No No 
121 m 24.5 UC 15.3 Pouchitis 6 No Yes 12 Yes No No 
131 m 38.0 UC 29.8 Pouchitis 6 No Yes 12 Yes No No 
141 f 35.5 UC 11.4 Pouchitis 6 No Yes 14+ No Yes (14 weeks 
+) 
No 
151 f 64.5 UC 57.7 Pouchitis 6 No Yes 7 Yes No No 
161 m 28.0 UC 20.0 Pouchitis 2X6 No Yes 40 Yes No No 
171 f 54.3 UC 40.2 Pouchitis 6 No Yes 91 Yes No No 
181 m 69.5 UC 44.6 Pouchitis 6 No No    No 
191, 2 m 21.5 UC 16.7 Pouchitis 6 No Yes 16 Yes No No 
201 m 23.7 UC 17.6 Pouchitis 6 No Yes 13+ No Yes (13 weeks 
+) 
No 
211 f 49.5 UC 31.2 Pouchitis 6 No Yes 28 Yes No No 
221 m 32.4 UC 13.6 Pouchitis 6 No No    No 
23 f 53.9 UC NA Ischemic 
pouchitis 
6 No No    No 
24 f 28.9 CD 11.1 Proctitis 1.5 Yes (after 10d due to lack 
of efficacy) 
No    No 
25 f 28.6 UC 18.4 Pouchitis 6 No Yes 12 Yes No No 
26 m 67.5 UC 59.0 Proctitis 6 No Yes 36+ No Yes (36 weeks 
+) 
No 
27 m 66.0 UC 22.9 Pouchitis 6 No Yes 12 Yes No No 
28 m 58.6 UC 37.3 Pouchitis 6 No Yes 4 Yes No No 
29 m 34.0 UC 22.1 Left-sided Colitis 6  No Yes 4 Yes No No 
30 m 69.5 UC 54.8 Left-sided Colitis 5 Yes (after 5 weeks due to 
lack of efficacy) 
No    No 
Supplementary Table 1: All patients treated with Alicaforsen. 1 Patients 10-22 have been previously described in the case series by Greuter et al. 2 
Patient 19 was re-treated with alicaforsen after first clinical improvement and relapse; patient 19 showed a second clinical improvement for 12 
weeks. 
Nr Sex Age in 
years (at 
treatment 
initiation) 
Age at 
UC 
Diagnosis 
Duration of 
UC (at 
treatment 
initiation) 
Montreal 
Classification 
History 
of C. 
difficile 
History of 
CMV 
colitis 
Smoking 
status 
Treatment ever received Surgical 
history 
Concomitant 
treatment 
1 f 44.2 38.6 5.7 E2 No No Never 5-ASA (oral and rectal), Budesonide (oral and 
rectal), systemic steroids, Entocort,  
Hydrocortisone (rectal)  
None None 
2 m 36.3 23.7 12.7 E2 No No Past 5-ASA (oral and rectal), Budesonide (oral and 
rectal), systemic steroids, Ciprofloxacin, AZA 
(10/2008-12/2011), Lecithin, rectal 
prednisolone and cinchocain.  
None Systemic steroids 
during the first 2 
weeks 
3 m 21.2 7.5 13.8 E1 No No Never Ipecacuanha, 5-ASA (oral and rectal), systemic 
steroids, Budesonide (rectal), Metronidazole  
None None 
4 m 17.0 15.5 1.5 E1 No No Never Budesonide (rectal), 5-ASA (oral and rectal), 
systemic steroids, Blueberries, Ginkgo, Chia 
Seed,  hempseed oil (oral) 
None None 
5 f 37.0 22.5 14.5 E2 No Yes Never 5-ASA (oral and rectal), systemic steroids, 
metronidazole, ciclosporin, AZA, Budesonide 
(oral), valaciclovir, rectal prednisolone 
None 5-ASA and AZA 
ongoing, 
systemic steroids 
during the first 2 
weeks 
6 f 46.0 33.2 12.8 E2 No No Never 5-ASA (oral and rectal), Budesonide (rectal), 
systemic steroids 
None 5-ASA and 
Budesonide 
ongoing 
7 f 30.6 25.0 5.6 E1 No No Never Systemic steroids, AZA, Budesonide (rectal), 5-
ASA (rectal) 
None None 
8 f 28.5 25.7 2.8 E2 No No Never Budesonide (rectal), 5-ASA (rectal), rectal 
prednisolon and cinchocain. 
None None 
9 N.A. 69.0 N.A. N.A. E1 No No N.A. N.A. None None 
10 m 67.5 59.0 8.5 E1 No No Past AZA, MTX, anti-TNF (2x) Left-sided 
hemicolectomy 
due to sigma 
perforation 
5-ASA (oral and 
rectal) ongoing 
11 m 34.0 22.1 11.8 E2 No No Past 5-ASA, AZA, anti-TNF (3x) None 5-ASA (oral), AZA 
and anti-TNF 
ongoing 
12 m 69.5 54.8 14.8 E2 No No Past AZA, systemic steroids, budesonide, anti-TNF 
(1x) 
None Anti-TNF ongoing 
Supplementary Table 1: Patient demographics and past medical history. 5-ASA, mesalazine; AZA, azathioprine; C, Clostridium; MTX, methotrexate; 
UC, ulcerative colitis 
Nr Sex Age 
in 
years  
Duration 
of 
treatment 
in weeks 
Indication for 
treatment 
Number 
of daily 
stools 
before 
treatment 
Number 
of daily 
stools 
after 
treatment 
Partial 
Mayo 
Score 
before 
treatment 
Partial 
Mayo 
Score 
after 
treatment 
6-point 
symptom 
scale pre 
treatment 
6-point 
symptom 
scale 
after 
treatment 
FC before 
treatment 
(μg/g) 
FC after 
treatment 
(μg/g) 
Endoscopy 
before 
treatment 
Endoscopy 
after 
treatment 
 
Durability 
of 
Response 
(weeks) 
Improvement Relapse ADE 
1 f 44.2 6 Patient did not 
want systemic 
therapy 
10 1.5 8 1 5 1 1110 16 3 NA 112 Yes Yes No 
2 m 36.3 6 Malcompliance, 
patient did not 
want AZA 
5.5 1 8 0 5 0 401 NA 3 2 18 Yes Yes No 
3 m 21.2 6 Patient did not 
want systemic 
therapy 
3 1 5 0 3 0 743 16 3 NA 73+ Yes No No 
4 m 17.0 6 Patient did not 
want systemic 
therapy 
1 1 1 0 0 0 116 9 3 0 69+ Yes No No 
5 f 37.0 6 Severe disease 
course despite 
5-ASA, topical 
steroids and 
AZA 
8 1 8 0 5 0 498 328 3 NA 8 Yes Yes No 
6 f 46.0 6 Patient did not 
want systemic 
therapy 
6 3 8 2 5 1 351 NA 3 NA 1 Yes Yes No 
7 f 30.6 6 Patient did not 
want systemic 
therapy 
8 8 8 8 5 5 NA NA 3 3  No  No 
8 f 28.5 6 Patient did not 
tolerate 5-ASA, 
pregnancy 
2 1 3 0 2 0 360 NA 1 3 1 Yes Yes No 
9 NA NA 6 NA 8 4.5 5 2 3 1 NA NA 2 1 NA Yes Yes No 
10 m 67.5 6 Patient did not 
want systemic 
3 2 4 2 2 1 337 506.3 3 NA 36 Yes No No 
therapy 
11 m 34.0 6 Left-sided 
colitis prior to 
anti-TNF 
10 4 8 5 5 3 NA NA 2 2 4 Yes Yes No 
12 m 69.5 5 Left-sided 
colitis prior to 
anti-TNF switch 
10 20 6 9 4 5 443.5 314.4 2 2  No  No 
Supplementary Table 2: Response to Alicaforsen treatment. ADE, adverse drug events; 5-ASA, mesalazine; AZA, azathioprine; FC, fecal 
calprotectin 


